Home > Insider Trading > Filing (0001209191-15-050818)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1501756	Avalanche Biotechnologies Inc.	AAVL	Biological Products, (No Disgnostic Substances) (2836)	205258327

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1614875	Mehdi Gasmi	C/O Avalanche Biotechnologies, Inc. 1035 O'Brien Drive, Suite A Menlo Park CA 94025	Vp, Pharmaceutical Development	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2015-05-28	500	$2.75	7,500	No	4	M	Direct
Common Stock	Disposition	2015-05-28	500	$38.02	7,000	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2015-05-28	500	$0.00	500	$2.75

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
96,000		2024-03-04	No	4	M	Direct

Footnotes

This amendment is being filed to correct an administrative error regarding the signatory of the Form 4.
Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.
This transaction was executed in multiple trades in prices ranging from $37.53 to $38.32, inclusive. The price reported in Column 4 above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Twenty-five percent (25%) of the shares subject to the option vested and became exercisable on the first anniversary measured from March 5, 2014, and the remaining shares subject to the option vest and become exercisable in 36 successive, equal monthly installments thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.